Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1983 May;49(5):405–409. doi: 10.1136/hrt.49.5.405

Prostaglandins and the cardiovascular system.

J R Vane
PMCID: PMC481324  PMID: 6340706

Full text

PDF
405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araki H., Lefer A. M. Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol. 1980 Feb;238(2):H176–H181. doi: 10.1152/ajpheart.1980.238.2.H176. [DOI] [PubMed] [Google Scholar]
  2. Belch J. J., McKay A., McArdle B., Leiberman P., Pollock J. G., Lowe G. D., Forbes C. D., Prentice C. R. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet. 1983 Feb 12;1(8320):315–317. doi: 10.1016/s0140-6736(83)91625-2. [DOI] [PubMed] [Google Scholar]
  3. Belch J. J., Newman P., Drury J. K., Capell H., Leiberman P., James W. B., Forbes C. D., Prentice C. R. Successful treatment of Raynaud's Syndrome with prostacyclin. Thromb Haemost. 1981 Jun 30;45(3):255–256. [PubMed] [Google Scholar]
  4. Belch J. J., Newman P., Drury J. K., McKenzie F., Capell H., Leiberman P., Forbes C. D., Prentice C. R. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet. 1983 Feb 12;1(8320):313–315. doi: 10.1016/s0140-6736(83)91624-0. [DOI] [PubMed] [Google Scholar]
  5. Bergman G., Daly K., Atkinson L., Rothman M., Richardson P. J., Jackson G., Jewitt D. E. Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet. 1981 Mar 14;1(8220 Pt 1):569–572. doi: 10.1016/s0140-6736(81)92028-6. [DOI] [PubMed] [Google Scholar]
  6. Budd G. T., Bukowski R. M., Lucas F. V., Cato A. E., Cocchetto D. M. Prostacyclin therapy of thrombotic thrombocytopenic purpura. Lancet. 1980 Oct 25;2(8200):915–915. doi: 10.1016/s0140-6736(80)92071-1. [DOI] [PubMed] [Google Scholar]
  7. Chierchia S., Patrono C., Crea F., Ciabattoni G., De Caterina R., Cinotti G. A., Distante A., Maseri A. Effects of intravenous prostacyclin in variant angina. Circulation. 1982 Mar;65(3):470–477. doi: 10.1161/01.cir.65.3.470. [DOI] [PubMed] [Google Scholar]
  8. Dembinska-Kiec A., Kostka-Trabka E., Gryglewski R. J. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemost. 1982 Apr 30;47(2):190–190. [PubMed] [Google Scholar]
  9. Dowd P. M., Martin M. F., Cooke E. D., Bowcock S. A., Jones R., Dieppe P. A., Kirby J. D. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol. 1982 Jan;106(1):81–89. doi: 10.1111/j.1365-2133.1982.tb00905.x. [DOI] [PubMed] [Google Scholar]
  10. Fidler J., Bennett M. J., de Swiet M., Ellis C., Lewis P. J. Treatment of pregnancy hypertension with prostacyclin. Lancet. 1980 Jul 5;2(8184):31–32. doi: 10.1016/s0140-6736(80)92904-9. [DOI] [PubMed] [Google Scholar]
  11. Fletcher J. R., Ramwell P. W. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs. Circ Shock. 1980;7(3):299–308. [PubMed] [Google Scholar]
  12. Friedenberg W. R., Myers W. O., Plotka E. D., Beathard J. N., Kummer D. J., Gatlin P. F., Stoiber D. L., Ray J. F., 3rd, Sautter R. D. Platelet dysfunction associated with cardiopulmonary bypass. Ann Thorac Surg. 1978 Apr;25(4):298–305. doi: 10.1016/s0003-4975(10)63545-x. [DOI] [PubMed] [Google Scholar]
  13. Friedman P. L., Brown E. J., Jr, Gunther S., Alexander R. W., Barry W. H., Mudge G. H., Jr, Grossman W. Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. N Engl J Med. 1981 Nov 12;305(20):1171–1175. doi: 10.1056/NEJM198111123052002. [DOI] [PubMed] [Google Scholar]
  14. Gimson A. E., Braude S., Mellon P. J., Canalese J., Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet. 1982 Sep 25;2(8300):681–683. doi: 10.1016/s0140-6736(82)90711-5. [DOI] [PubMed] [Google Scholar]
  15. Gimson A. E., Langley P. G., Hughes R. D., Canalese J., Mellon P. J., Williams R., Woods H. F., Weston M. J. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet. 1980 Jan 26;1(8161):173–175. doi: 10.1016/s0140-6736(80)90661-3. [DOI] [PubMed] [Google Scholar]
  16. Goehlert U. G., Ng Ying Kin N. M., Wolfe L. S. Biosynthesis of prostacyclin in rat cerebral microvessels and the choroid plexus. J Neurochem. 1981 Mar;36(3):1192–1201. doi: 10.1111/j.1471-4159.1981.tb01718.x. [DOI] [PubMed] [Google Scholar]
  17. Gryglewski R. J., Nowak S., Kostka-Trabka E., Bieroń K., Dembińska-Kieć A., Błaszczyk B., Kuśmiderski J., Markowska E., Szmatoła S. Clinical use of prostacyclin (PGI2) in ischaemic stroke. Pharmacol Res Commun. 1982 Oct;14(9):879–908. doi: 10.1016/s0031-6989(82)80012-x. [DOI] [PubMed] [Google Scholar]
  18. Hall R. J., Dewar H. A. Safety of coronary arterial prostacyclin infusion. Lancet. 1981 Apr 25;1(8226):949–949. doi: 10.1016/s0140-6736(81)91648-2. [DOI] [PubMed] [Google Scholar]
  19. Hensby C. N., Lewis P. J., Hilgard P., Mufti G. J., Hows J., Webster J. Prostacyclin deficiency in thrombotic thrombocytopenic purpura. Lancet. 1979 Oct 6;2(8145):748–748. doi: 10.1016/s0140-6736(79)90680-9. [DOI] [PubMed] [Google Scholar]
  20. Hirsh P. D., Firth B. G., Campbell W. B., Willerson J. T., Hillis L. D. Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. Am Heart J. 1982 Aug;104(2 Pt 1):234–237. doi: 10.1016/0002-8703(82)90198-3. [DOI] [PubMed] [Google Scholar]
  21. Hory B., Saunier F., Roy C., Renevier A., Kieffer Y., Saint-Hillier Y., Perol C. Comparaison de la prostacycline et de l'heparinisation régionale au cours de la séance d'hémodialyse. Nouv Presse Med. 1982 Jul 10;11(32):2393–2397. [PubMed] [Google Scholar]
  22. Krausz M. M., Utsunomiya T., Feuerstein G., Wolfe J. H., Shepro D., Hechtman H. B. Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest. 1981 Apr;67(4):1118–1125. doi: 10.1172/JCI110125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lefer A. M., Ogletree M. L., Smith J. B., Silver M. J., Nicolaou K. C., Barnette W. E., Gasic G. P. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science. 1978 Apr 7;200(4337):52–54. doi: 10.1126/science.345441. [DOI] [PubMed] [Google Scholar]
  24. Lefer A. M., Tabas J., Smith E. F., 3rd Salutary effects of prostacyclin in endotoxic shock. Pharmacology. 1980;21(3):206–212. doi: 10.1159/000137434. [DOI] [PubMed] [Google Scholar]
  25. Leithner C., Sinzinger H., Schwarz M. Treatment of chronic kidney transplant rejection with prostacyclin - reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. Prostaglandins. 1981 Nov;22(5):783–788. doi: 10.1016/0090-6980(81)90217-3. [DOI] [PubMed] [Google Scholar]
  26. Longmore D. B., Bennett J. G., Hoyle P. M., Smith M. A., Gregory A., Osivand T., Jones W. A. Prostacyclin administration during cardiopulmonary bypass in man. Lancet. 1981 Apr 11;1(8224):800–804. doi: 10.1016/s0140-6736(81)92680-5. [DOI] [PubMed] [Google Scholar]
  27. Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol. 1982 May;76(1):3–31. doi: 10.1111/j.1476-5381.1982.tb09186.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Moncada S., Herman A. G., Higgs E. A., Vane J. R. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977 Sep;11(3):323–344. doi: 10.1016/0049-3848(77)90185-2. [DOI] [PubMed] [Google Scholar]
  29. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  30. Moncada S., Vane J. R. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull. 1978 May;34(2):129–135. doi: 10.1093/oxfordjournals.bmb.a071482. [DOI] [PubMed] [Google Scholar]
  31. Monden M., Fortner J. G. Twenty-four- and 48-hour canine liver preservation by simple hypothermia with prostacyclin. Ann Surg. 1982 Jul;196(1):38–42. doi: 10.1097/00000658-198207000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Moriau M., Masure R., Hurlet A., Debeys C., Chalant C., Ponlot R., Jaumain P., Servaye-Kestens Y., Ravaux A., Louis A. Haemostasis disorders in open heart surgery with extracorporeal circulation. Importance of the platelet function and the heparin neutralization. Vox Sang. 1977;32(1):41–51. doi: 10.1111/j.1423-0410.1977.tb00602.x. [DOI] [PubMed] [Google Scholar]
  33. Mundy A. R., Bewick M., Moncada S., Vane J. R. Short term suppression of hyperacute renal allograft rejection in presensitised dogs with prostacyclin. Prostaglandins. 1980 Apr;19(4):595–603. doi: 10.1016/s0090-6980(80)80009-8. [DOI] [PubMed] [Google Scholar]
  34. Olsson A. G. Intravenous prostacyclin for ischemic ulcers in peripheral artery disease. Lancet. 1980 Nov 15;2(8203):1076–1076. doi: 10.1016/s0140-6736(80)92290-4. [DOI] [PubMed] [Google Scholar]
  35. Pardy B. J., Lewis J. D., Eastcott H. H. Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease. Surgery. 1980 Dec;88(6):826–832. [PubMed] [Google Scholar]
  36. Ribeiro L. G., Brandon T. A., Hopkins D. G., Reduto L. A., Taylor A. A., Miller R. R. Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol. 1981 Apr;47(4):835–840. doi: 10.1016/0002-9149(81)90182-x. [DOI] [PubMed] [Google Scholar]
  37. Starnes V. A., Primm R. K., Woosley R. L., Oates J. A., Hammon J. W., Jr Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):765–769. doi: 10.1097/00005344-198209000-00011. [DOI] [PubMed] [Google Scholar]
  38. Szczeklik A., Gryglewski R. J., Nizankowski R., Musiał J., Pietoń R., Mruk J. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun. 1978 Jun;10(6):545–556. doi: 10.1016/s0031-6989(78)80053-8. [DOI] [PubMed] [Google Scholar]
  39. Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R. J. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1979 May 26;1(8126):1111–1114. doi: 10.1016/s0140-6736(79)91792-6. [DOI] [PubMed] [Google Scholar]
  40. Szczeklik J., Szczeklik A., Nizankowski R. Prostacyclin for pulmonary hypertension. Lancet. 1980 Nov 15;2(8203):1076–1076. doi: 10.1016/s0140-6736(80)92291-6. [DOI] [PubMed] [Google Scholar]
  41. Søreide O., Segadal L., Trippestad A., Engedal H. Salvage of the severely ischaemic limb by intra-arterial prostacyclin (PGI2) infusion. A case report. Scand J Thorac Cardiovasc Surg. 1982;16(1):71–73. doi: 10.3109/14017438209100613. [DOI] [PubMed] [Google Scholar]
  42. Turney J. H., Dodd N. J., Weston M. J. Prostacyclin in extracorporeal circulations. Lancet. 1981 May 16;1(8229):1101–1101. doi: 10.1016/s0140-6736(81)92264-9. [DOI] [PubMed] [Google Scholar]
  43. Turney J. H., Weston M. J. Dialysis without anticoagulants. Lancet. 1981 Sep 26;2(8248):693–693. doi: 10.1016/s0140-6736(81)91022-9. [DOI] [PubMed] [Google Scholar]
  44. Utsunomiya T., Krausz M. M., Kobayashi M., Shepro D., Hechtman H. B. Myocardial protection with prostacyclin after lethal endotoxemia. Surgery. 1982 Jul;92(1):101–108. [PubMed] [Google Scholar]
  45. Watkins W. D., Peterson M. B., Crone R. K., Shannon D. C., Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet. 1980 May 17;1(8177):1083–1083. doi: 10.1016/s0140-6736(80)91522-6. [DOI] [PubMed] [Google Scholar]
  46. Woods H. F., Ash G., Weston M. J., Bunting S., Moncada S., Vane J. R. Prostacyclin can replace heparin in haemodialysis in dogs. Lancet. 1978 Nov 18;2(8099):1075–1077. doi: 10.1016/s0140-6736(78)91806-8. [DOI] [PubMed] [Google Scholar]
  47. Yui Y., Nakajima H., Kawai C., Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982 Aug;50(2):320–324. doi: 10.1016/0002-9149(82)90183-7. [DOI] [PubMed] [Google Scholar]
  48. Zusman R. M., Rubin R. H., Cato A. E., Cocchetto D. M., Crow J. W., Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med. 1981 Apr 16;304(16):934–939. doi: 10.1056/NEJM198104163041603. [DOI] [PubMed] [Google Scholar]
  49. Zygulska-Mach H., Kostka-Trabka E., Nitoń A., Gryglewski R. J. Prostacyclin in central retinal vein occlusion. Lancet. 1980 Nov 15;2(8203):1075–1075. doi: 10.1016/s0140-6736(80)92289-8. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES